Humana Inc (NYSE:HUM) has been given a consensus recommendation of “Buy” by the nineteen brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $325.00.
Several brokerages have weighed in on HUM. Citigroup boosted their price objective on Humana from $340.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Cantor Fitzgerald raised Humana from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $300.00 to $345.00 in a report on Monday, August 12th. Mizuho began coverage on Humana in a report on Thursday, October 17th. They set a “buy” rating and a $316.00 price objective for the company. Morgan Stanley dropped their price objective on Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a report on Thursday, September 26th. Finally, JPMorgan Chase & Co. boosted their price objective on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.
In other news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.54% of the company’s stock.
NYSE:HUM traded up $17.55 on Monday, hitting $335.55. 2,070,329 shares of the stock were exchanged, compared to its average volume of 979,419. The stock has a market capitalization of $42.23 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 1.37 and a beta of 0.85. Humana has a 52 week low of $225.65 and a 52 week high of $340.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.83 and a current ratio of 1.83. The company’s 50-day moving average price is $282.93 and its 200 day moving average price is $273.10.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The firm had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 22.32% and a net margin of 4.06%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business posted $4.58 EPS. As a group, equities research analysts predict that Humana will post 17.77 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.66%. Humana’s dividend payout ratio (DPR) is presently 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: What are the benefits of buying treasury bonds?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.